Research progress in immunotherapy of advanced non-small cell lung cancer

Xiaojuan Lu, Huaqiu Shi, Qiuyang Que, Song Qiu

Article ID: 1367
Vol 5, Issue 2.1, 2021

VIEWS - 43 (Abstract) 33 (PDF)

Abstract


Non-small cell lung cancer (NSCLC) poses a serious threat to people’s health. Its morbidity and mortality are among the highest among all malignant tumors, and there is an urgent need for more effective new treatment methods. In recent years, NSCLC immunotherapy has made great progress, the first PD-1 inhibitor nivolumab (Nivolumab, O drug) was approved by the US Food and Drug Administration (FDA) in March 2015, applying to the patients who progressed or has received platinum chemotherapy drugs in the past. Immunotherapy of advanced NSCLC has entered a new era. This article reviews the current research progress of NSCLC immunotherapy.


Keywords


Non-small Cell Lung Cancer (NSCLC); Immunotherapy; Chemotherapy; Radiotherapy; Targeted Therapy

Full Text:

PDF


References


1. Lancet T. Globocan 2018: counting the toll of cancer. Lancet 2018; 392(10152): 985.

2. Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell 2020; 37(4): 443–455.

3. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small cell lung cancer (POPLAR): a multicenter, open-label, phase 2 randomized controlled trial. The Lancet 2016; 387(10030): 1837–1846.

4. Espana S, Guasch E, Carceren Y, et al. Immunotherapy rechallenge in patients with non-small cell lung cancer. Pulmonology 2020; 26(4): 252–254.

5. Duan J, Cui L, Zhao X, et al. Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer. JAMA Oncology 2020; 6(3): 375–385.

6. Dunn GP, Old LJ, Schreiber RD, et al. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21(2): 137–148.

7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646–674.

8. Rossi G, Russo A, Tagliamento M, et al. Precision medicine for NSCLC in the era of immunotherapy: new biomarkers to select the most suitable treatment or the most suitable patient. Cancers (Basel) 2020; 12(5): 1125.

9. Giaccone G, Bazhenova LA, Nemunaitis J, et al. A phase Ⅲ study of belagenpumatucel-L, an allogeneic tumor cell vaccine, as maintenance therapy for non-small cell lung cancer. European Journal of Cancer 2015; 51(16): 2321–2329.

10. Sanborn RE, ROSS HJ, Aung S, et al. A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer. Journal of Immunotherapy Cancer 2017; 5(1): 103.

11. Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clinical Cancer Research 2011; 17(22): 6958–6962.

12. Planchard D, Reinmuth N, Orlov S, et al. ARCTIC: durvalumab with or without tremelimumab as third- line or later treatment of metastatic non-small cell lung cancer. Annals Oncology 2020; 31(5): 609–618.

13. Alsaab HO, Samaresh S, Raimi A, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Frontiers Pharmacology 2017; 8: 561.

14. Jia LL, Walsh RJ, Ang Y, et al. The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer. Therapeutic Advances Medical Oncology 2019; 11: 1–22.

15. Osmani L, Askin F, Gabrielson E, et al. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Seminars in Cancer Biology 2018; 52(Pt 1): 103–109.

16. Califano R, Gomes F, Ackermann CJ, et al. Immune checkpoint blockade for non-small cell lung cancer: what is the role in the special populations? European Journal of Cancer 2020; 125: 1–11.

17. Rocco D, Malapelle U, Marzia DR, et al. Pharmacodynamics of current and emerging PD-1 and PD-L1 inhibitors for the treatment of non-small cell lung cancer. Expert Opinion Drug Metabolism Toxicology 2020; 16(2): 87–96.

18. Leonetti A, Wever B, Mazzaschiet G, et al. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer. Drug Resistance Updates 2019; 46: 100644.

19. Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small cell lung cancer: a randomized, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncology 2016; 17(11): 1497–1508.

20. Chen Y, Zhou Y, Lu T, et al. Immune-checkpoint inhibitors as the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. Journal of Cancer 2019; 10(25): 6261–6268.

21. Gouveia AG, Zalay OC, Chua KL, et al. Response evaluation after stereotactic ablative radiotherapy for localized non-small cell lung cancer: an equipoise of available resource and accuracy. The British Journal of Radiology 2020; 93(1106): 100644.

22. D’Aandrea MA, Kesava Reddy G. Systemic immunostimulatory effects of radiation therapy improves the outcomes of patients with advanced NSCLC receiving immunotherapy. American Journal of Clinical Oncology 2020; 43(3): 218–228.

23. Spaas M, Lievens Y. Is the combination of immunotherapy and radiotherapy in non-small cell lung cancer a feasible and effective approach? Frontiers in Medicine (Lausanne) 2019; 6: 244–260.

24. Besse B, Garrido P, Bennouna J, et al. Safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer (NSCLC): a phase 1b expansion cohort study. Annals of Oncology 2016; 27(Suppl.6): vi436.

25. Gahr S, Stoehr R, Geissinger E, et al. EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. British Journal of Cancer 2013; 109(7): 1821–1828.

26. Lisberg A, Cummings A, Goldman JW, et al. A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine kinase inhibitor (TKI) naïve patients with advanced NSCLC. Journal of Thoracic Oncology 2018; 13(8): 1138–1145.

27. Qiang H, Chang Q, Xu J, et al. New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer. Journal of Cancer Research Clinical Oncology 2020; 146(3): 631–645.

28. Shiraishi Y, Kishimoto J, Tanaka K, et al. Treatment rationale and design for APPLE (WJOG11218L): a multicenter, open-label, randomized phase 3 study of atezolizumab and platinum/pemetrexed with or without bevacizumab for patients with advanced nonsquamous non-small cell lung cancer. Clinical Lung Cancer 2020; 21(5): 472–476.

29. Dong J, Li B, Zhou Q, et al. Advances in evidence based medicine for immunotherapy of non-small cell lung cancer. Journal of Evidence-Based Medicine 2018; 11(4): 278–287.

30. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. New England Journal of Medicine 2018; 378(22): 2093–2104.

31. O’byrne KJ, Lee KH, Kim SW, et al. 1274P First line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in Asian patients (pts) with advanced non-small cell lung cancer (aNSCLC) in CheckMate 227. Annals of Oncology 2020; 31(Suppl.4): S824.

32. John T, Sakai H, Ikeda S, et al. 1311P First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + chemotherapy (chemo) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC) from CheckMate 9LA. Annals of Oncology 2020; 31(Suppl.4): S847–S848.




DOI: https://doi.org/10.24294/ti.v5.i2.1.1367

Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Xiaojuan Lu, Huaqiu Shi, Qiuyang Que, Song Qiu

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This site is licensed under a Creative Commons Attribution 4.0 International License.